Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 9, Pages 2165-2173Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2013.871277
Keywords
Myeloma; p53; bendamustine; melphalan; drug resistance; cell cycle and apoptosis changes
Categories
Funding
- CHUM foundation (Centre Hospitalier de l'Universit de Montreal, Montreal, Canada)
- Canceropole Grand-Ouest
- MundiPharma
- Actions Cancer 44
Ask authors/readers for more resources
Because the old alkylating drug bendamustine (BDM) is currently under evaluation in patients with multiple myeloma, we compared its efficacy to that of melphalan in 29 human myeloma cell lines (HMCLs). The concentrations of BDM and melphalan that killed 50% of cells (LD50) in HMCLs were linearly correlated (p < 0.001), and reactive oxygen (ROS) scavengers similarly inhibited cell death induced by both drugs. Sensitivity of HMCLs to both drugs was correlated to p53: the BDM and melphalan median LD50 values of TP53(wild-type) HMCLs were more than two-fold lower than those of TP53(abnormal) HMCLs (p < 0.001), and p53 silencing in TP53(wt) NCI-H929 cells inhibited BDM- and melphalan-induced cell death. Both drugs induced expression of p53 targets, p21, Puma and DR5, only in TP53wt HMCLs. In primary cells, both drugs induced an increase in DR5 expression in cells without del(17p). Finally, we demonstrated that the combined effect of BDM and melphalan was additive, and that BDM did not overcome melphalan resistance and vice versa.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available